Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


26/09/2016
First Patient at Moffitt dosed in Phase 1b/2 breast trial
13/09/2016
Rodman & Renshaw Global Investment Conference Presentation
13/09/2016
PTX presents at Rodman & Renshaw Investment Conference
31/08/2016
Appendix 4G and Corporate Governance Statement
31/08/2016
Appendix 4E and 2016 Annual Report
04/08/2016
USPTO Grants Allowances for Two PTX-200 Patents